Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers
REPORT SCOPE
The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.
REPORT INCLUDES
The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.
REPORT INCLUDES
- An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed
- Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies
- A brief examination of the patent landscape
- Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor
- Coverage of number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use
- Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth
CHAPTER 1 ADOPTIVE TRANSFER OF AUTOLOGOUS LYMPHOCYTES TARGETING SOMATICALLY MUTATED GENES
Key Findings
Tumor-Infiltrating Lymphocytes (TILs): A New and Exciting Era in Cancer Treatments
Adoptive Cell Transfer (ACT) and Therapeutic TILs
Ground-Breaking Management of Advanced Metastatic Breast Cancer
Successful Advances in TILs Therapies for Cholangiocarcinoma
Hope for Immunotherapy Treatments of Gastrointestinal Cancers
Limitations of ACT and Therapeutic TILs
Overcoming the Limitations of ACT and Therapeutic TILs
Expanding Clinical Trial Portfolio
Complexities of the TILs Patent Landscape
What's Next for TILs?
Outlook and Implications
CHAPTER 2 REFERENCES
CHAPTER 3 A NOTE FROM THE EDITOR
CHAPTER 4 ANALYST CREDENTIALS
Key Findings
Tumor-Infiltrating Lymphocytes (TILs): A New and Exciting Era in Cancer Treatments
Adoptive Cell Transfer (ACT) and Therapeutic TILs
Ground-Breaking Management of Advanced Metastatic Breast Cancer
Successful Advances in TILs Therapies for Cholangiocarcinoma
Hope for Immunotherapy Treatments of Gastrointestinal Cancers
Limitations of ACT and Therapeutic TILs
Overcoming the Limitations of ACT and Therapeutic TILs
Expanding Clinical Trial Portfolio
Complexities of the TILs Patent Landscape
What's Next for TILs?
Outlook and Implications
CHAPTER 2 REFERENCES
CHAPTER 3 A NOTE FROM THE EDITOR
CHAPTER 4 ANALYST CREDENTIALS
LIST OF TABLES
Table 1: Overview of PD-1/PD-L1 inhibitors, Mechanisms of Action, Trial Designations and Approved Companion Diagnostics
Table 2: Commonly Used Acronyms Associated with Adoptive Transfer of Autologous TILs Therapy
Table 1: Overview of PD-1/PD-L1 inhibitors, Mechanisms of Action, Trial Designations and Approved Companion Diagnostics
Table 2: Commonly Used Acronyms Associated with Adoptive Transfer of Autologous TILs Therapy
LIST OF FIGURES
Figure 1: Schematic of Adoptive Cell Transfer (ACT) Therapies
Figure 2: Schematic of Tumor-Infiltrating Lymphocytes (TILs) Therapies
Figure 3: Number of Clinical Trials Incorporating Tumor-Infiltrating Lymphocytes (TILs) Activity, by Phase and Year, by Study Start Date, 2005-2018*
Figure 4: Clinical Pipeline Iovance Biotherapeutics
Figure 1: Schematic of Adoptive Cell Transfer (ACT) Therapies
Figure 2: Schematic of Tumor-Infiltrating Lymphocytes (TILs) Therapies
Figure 3: Number of Clinical Trials Incorporating Tumor-Infiltrating Lymphocytes (TILs) Activity, by Phase and Year, by Study Start Date, 2005-2018*
Figure 4: Clinical Pipeline Iovance Biotherapeutics
